Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback